Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (327) 327
Publication (21) 21
Book / eBook (7) 7
Book Chapter (2) 2
Book Review (2) 2
Dissertation (2) 2
Conference Proceeding (1) 1
Magazine Article (1) 1
Newspaper Article (1) 1
Patent (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (168) 168
index medicus (147) 147
male (131) 131
female (126) 126
middle aged (114) 114
gastroenterology & hepatology (106) 106
adult (103) 103
antiviral agents - therapeutic use (74) 74
aged (66) 66
hepatitis c (62) 62
treatment outcome (61) 61
drug therapy, combination (55) 55
ribavirin (53) 53
genotype (51) 51
hepatitis (50) 50
hepatitis c, chronic - drug therapy (50) 50
health aspects (46) 46
hepacivirus - genetics (46) 46
hepatitis c virus (46) 46
antiviral agents - adverse effects (45) 45
gastroenterology and hepatology (42) 42
abridged index medicus (41) 41
hepatitis b (39) 39
interferon (39) 39
care and treatment (38) 38
liver cirrhosis (38) 38
cirrhosis (37) 37
therapy (36) 36
young adult (36) 36
analysis (34) 34
hepatitis b, chronic - drug therapy (34) 34
antiviral agents - administration & dosage (32) 32
drug therapy (32) 32
lamivudine (31) 31
sofosbuvir (30) 30
clinical trials (29) 29
liver (29) 29
medicine, general & internal (29) 29
double-blind method (28) 28
adolescent (27) 27
ribavirin - therapeutic use (27) 27
transplantation (27) 27
viral load (27) 27
liver transplantation (26) 26
patients (26) 26
antiviral agents (25) 25
genetic aspects (25) 25
hepatocellular-carcinoma (25) 25
surgery (25) 25
infection (24) 24
infections (24) 24
hepacivirus - drug effects (23) 23
research (23) 23
hepatitis c - drug therapy (22) 22
time factors (22) 22
adefovir dipivoxil (20) 20
disease (19) 19
hcv (19) 19
hepatitis b virus - genetics (19) 19
hepatology (19) 19
interferon-alpha - therapeutic use (19) 19
risk factors (19) 19
rna, viral - blood (19) 19
biological response modifiers (18) 18
chronic infection (18) 18
drug administration schedule (18) 18
safety (18) 18
virus-infection (18) 18
genotype & phenotype (17) 17
hepatitis c, chronic - virology (17) 17
new zealand (17) 17
virus (17) 17
dna, viral - blood (16) 16
follow-up studies (16) 16
genotypes (16) 16
resistance (16) 16
tenofovir (16) 16
uridine monophosphate - analogs & derivatives (16) 16
adenine - analogs & derivatives (15) 15
combination (15) 15
efficacy (15) 15
entecavir (15) 15
hepatitis b e antigens - blood (15) 15
hepatitis b virus - immunology (15) 15
hepatitis b, chronic - virology (15) 15
mortality (15) 15
plus ribavirin (15) 15
protease inhibitors (15) 15
recurrence (15) 15
hepatitis b virus (14) 14
hepatitis c - complications (14) 14
infectious diseases (14) 14
proteases (14) 14
retrospective studies (14) 14
ribavirin - adverse effects (14) 14
studies (14) 14
sustained virologic response (14) 14
transplantation of organs, tissues, etc (14) 14
aged, 80 and over (13) 13
alanine transaminase - blood (13) 13
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Robarts - Stacks (2) 2
UTL at Downsview - May be requested (2) 2
UofT at Scarborough - Stacks (2) 2
Collection Dvlpm't (Acquisitions) - Vendor file (1) 1
Engineering & Comp. Sci. - Stacks (1) 1
Gerstein Science - Stacks (1) 1
OISE - Storage (1) 1
Robarts - Searching (1) 1
Trinity College (John W Graham) - Stacks (1) 1
UofT at Mississauga - Stacks (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text The authors reply
by Lawitz, Eric and Gane, Edward J
New England Journal of Medicine, ISSN 0028-4793, 2013, Volume 369, Issue 7, pp. 678 - 679
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Is hepatitis B immune globulin still needed after liver transplantation for chronic hepatitis B?
: Gane
by Gane, Edward J
Hepatology, ISSN 0270-9139, 10/2017, Volume 66, Issue 4, pp. 1023 - 1025
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text The natural history of recurrent hepatitis C and what influences this
by Gane, Edward J
Liver Transplantation, ISSN 1527-6465, 10/2008, Volume 14, Issue S2, pp. S36 - S44
1. Liver failure and liver cancer from chronic hepatitis C are the most common indications for liver transplantation and numbers of both are projected to... 
LIVER-TRANSPLANT RECIPIENTS | UNITED-STATES | INTERFERON TREATMENT | SURGERY | VIRUS-INFECTION | HCV-RELATED DISEASE | ALLOGRAFT CIRRHOSIS | FIBROSIS PROGRESSION | TRANSPLANTATION | HEPATOCELLULAR-CARCINOMA | DONOR AGE | GASTROENTEROLOGY & HEPATOLOGY | REJECTION EPISODES | Liver Neoplasms - virology | Recurrence | Reoperation | Liver Transplantation | Humans | Risk Factors | Graft Survival | Carcinoma, Hepatocellular - virology | Cholestasis - virology | Hepatitis C - surgery | Immunosuppression | Hepatitis C - complications | Hepatitis C - physiopathology
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Reply
by Plank, Lindsay D and McCall, John L and Gane, Edward J
Hepatology, ISSN 0270-9139, 05/2016, Volume 63, Issue 5, pp. 1742 - 1743
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Reply
by Lindsay D Plank and John L McCall and Edward J Gane
Hepatology, ISSN 0270-9139, 05/2016, Volume 63, Issue 5, p. 1742
Journal Article
Details down arrow
6. Full Text Reply
by Plank, Lindsay D and McCall, John L and Gane, Edward J
Hepatology, ISSN 0270-9139, 05/2016, Volume 63, Issue 5, pp. 1742 - 1743
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Reply
by Plank, Lindsay D and Mccall, John L and Gane, Edward J
Hepatology, ISSN 0270-9139, 05/2016, Volume 63, Issue 5, pp. 1742 - 1743
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Is hepatitis B immune globulin still needed after liver transplantation for chronic hepatitis B?
by Gane, Edward J
Hepatology, ISSN 0270-9139, 10/2017, Volume 66, Issue 4, pp. 1023 - 1025
LAMIVUDINE | PROPHYLAXIS | ENTECAVIR | HEPATOCELLULAR-CARCINOMA | VIRUS RECURRENCE | RISK | SURFACE-ANTIGEN | HBV-RELATED CIRRHOSIS | RECIPIENTS | GASTROENTEROLOGY & HEPATOLOGY | WITHDRAWAL | Immunoglobulins | Allografts | Globulins | Syngeneic grafts | Transplantation | Hepatitis B | Liver transplantation
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Future anti‐HBV strategies
by Gane, Edward J
Liver International, ISSN 1478-3223, 01/2017, Volume 37, Issue S1, pp. 40 - 44
Although current oral antivirals can maintain viral suppression and reduce the risk of liver‐related complications, lifelong therapy is associated with high... 
ccc | immunomodulator | RNA | Cure | DNA | HBV | silencing | core inhibitor | HBV Cure | siRNA | cccDNA silencing | HEPATITIS-B-VIRUS | THERAPEUTIC VACCINE | GS-4774 | REPLICATION | INFECTION | GASTROENTEROLOGY & HEPATOLOGY | ARC-520 | Virus Replication - drug effects | Antiviral Agents - pharmacology | Hepatitis B, Chronic - immunology | Humans | RNA, Small Interfering - pharmacology | Hepatitis B virus - physiology | Hepatitis B Surface Antigens - blood | Randomized Controlled Trials as Topic | Hepatitis B, Chronic - virology | Hepatitis B Vaccines - therapeutic use | Hepatitis B, Chronic - drug therapy | DNA, Circular - blood | Hepatitis B Core Antigens | Drug Design | Hepatitis B surface antigen | Immune response | Toxicity | Complications | Immunomodulation | Liver | Immune clearance | Chronic infection | Risk reduction | Activation | Lymphocytes T | Infections | Vaccines | Polymerase | Silence | Inhibitors | Immune checkpoint | Exhaustion | Life cycle engineering | Life cycles
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection
by Foster, Graham R and Afdhal, Nezam and Roberts, Stuart K and Bräu, Norbert and Gane, Edward J and Pianko, Stephen and Lawitz, Eric and Thompson, Alex and Shiffman, Mitchell L and Cooper, Curtis and Towner, William J and Conway, Brian and Ruane, Peter and Bourlière, Marc and Asselah, Tarik and Berg, Thomas and Zeuzem, Stefan and Rosenberg, William and Agarwal, Kosh and Stedman, Catherine A.M and Mo, Hongmei and Dvory-Sobol, Hadas and Han, Lingling and Wang, Jing and McNally, John and Osinusi, Anu and Brainard, Diana M and McHutchison, John G and Mazzotta, Francesco and Tran, Tram T and Gordon, Stuart C and Patel, Keyur and Reau, Nancy and Mangia, Alessandra and Sulkowski, Mark and ASTRAL-2 & ASTRAL-3 Investigators and ASTRAL-3 Investigators and ASTRAL-2 Investigators
The New England Journal of Medicine, ISSN 0028-4793, 12/2015, Volume 373, Issue 27, pp. 2608 - 2617
In two phase 3 trials involving patients with hepatitis C virus infection, including those with cirrhosis, 12 weeks of sofosbuvir–velpatasvir resulted in a... 
MEDICINE, GENERAL & INTERNAL | C VIRUS-INFECTION | Humans | Middle Aged | Drug Resistance, Viral | Hepacivirus - genetics | Hepatitis C, Chronic - virology | Male | Hepatitis C, Chronic - complications | Young Adult | Heterocyclic Compounds, 4 or More Rings - therapeutic use | Aged, 80 and over | Adult | Female | Sofosbuvir - adverse effects | Sofosbuvir - therapeutic use | Liver Cirrhosis - drug therapy | Liver Cirrhosis - etiology | Antiviral Agents - therapeutic use | Genotype | Heterocyclic Compounds, 4 or More Rings - adverse effects | Treatment Outcome | Hepatitis C, Chronic - drug therapy | Antiviral Agents - adverse effects | Carbamates - adverse effects | Aged | Carbamates - therapeutic use | Viral Nonstructural Proteins - antagonists & inhibitors | Drug Combinations | Clinical trials | Usage | Genetic aspects | Research | Hepatitis C virus | Headache | Fatigue | Infections | Nausea | Patients | Ribavirin | Studies | Cirrhosis | Sleep disorders | Genotype & phenotype | Hepatitis | Hepatitis C | Drug therapy | Genotypes | Pharmaceuticals
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text Hepatitis B-positive donors in renal transplantation: Increasing the deceased donor pool
by Pilmore, Helen L and Gane, Edward J
Transplantation, ISSN 0041-1337, 08/2012, Volume 94, Issue 3, pp. 205 - 210
It is reasonable to transplant HbsAg-positive kidneys into recipients who are themselves hepatitis B surface antigen (HbsAg) positive with appropriate... 
Renal | Transplantation | Hepatitis B virus | SURGERY | KIDNEY ALLOGRAFT RECIPIENTS | LAMIVUDINE THERAPY | IMMUNOLOGY | INTRAMUSCULAR VACCINATION | DIALYSIS PATIENTS | IMMUNE-RESPONSES | HEMODIALYSIS-PATIENTS | SURFACE-ANTIGEN | C VIRUS | ANTIBODY-RESPONSE | VIRAL-HEPATITIS | Hepatitis B - metabolism | Prevalence | Kidney - pathology | Antiviral Agents - therapeutic use | Humans | Immunosuppressive Agents - therapeutic use | Hepatitis B - virology | Hepatitis B Surface Antigens - immunology | Risk | Kidney Transplantation - methods | Hepatitis B - transmission | Hepatitis B Vaccines - therapeutic use | Tissue and Organ Procurement - methods | Hepatitis B Antibodies - immunology | Tissue Donors | Kidney Transplantation - adverse effects
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
12. Author reply to: Hepatitis B reactivation in chronic hepatitis C patients during treatment with ledipasvir and sofosbuvir
by Gane, Edward J and Hyland, Robert H and An, Di and Svarovskaia, Evguenia S and Brainard, Diana and McHutchison, John G
Antiviral Therapy, ISSN 1359-6535, 2018, Volume 23, Issue 3, pp. 283 - 284
Journal Article
Details down arrow
13. Full Text Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial
by Manns, Michael, Prof and Samuel, Didier, Prof and Gane, Edward J, Prof and Mutimer, David, Prof and McCaughan, Geoff, Prof and Buti, Maria, Prof and Prieto, MartÍn, MD and Calleja, José Luis, MD and Peck-Radosavljevic, Markus, Prof and Müllhaupt, Beat, Prof and Agarwal, Kosh, MD and Angus, Peter, Prof and Yoshida, Eric M, MD and Colombo, Massimo, Prof and Rizzetto, Mario, Prof and Dvory-Sobol, Hadas, PhD and Denning, Jill, MA and Arterburn, Sarah, MS and Pang, Phillip S, MD and Brainard, Diana, MD and McHutchison, John G, MD and Dufour, Jean-François, MD and Van Vlierberghe, Hans, Prof and van Hoek, Bart, Prof and Forns, Xavier, MD and SOLAR-2 Investigators and SOLAR-2 investigators
Lancet Infectious Diseases, The, ISSN 1473-3099, 2016, Volume 16, Issue 6, pp. 685 - 697
Summary Background Treatment options are limited for patients infected by hepatitis C virus (HCV) with advanced liver disease. We assessed the safety and... 
Infectious Disease | INFECTIOUS DISEASES | THERAPY | HCV INFECTION | ADEFOVIR DIPIVOXIL | CIRRHOSIS | TRANSPLANTATION | Humans | Middle Aged | Fluorenes - therapeutic use | Liver Cirrhosis - mortality | Hepacivirus - genetics | Male | Hepatitis C, Chronic - complications | Hepatitis C, Chronic - mortality | Viral Load | Time Factors | Female | Drug Therapy, Combination | Benzimidazoles - therapeutic use | Uridine Monophosphate - therapeutic use | Hepacivirus - drug effects | Liver Cirrhosis - drug therapy | Global Health | Antiviral Agents - therapeutic use | Ribavirin - therapeutic use | Genotype | Treatment Outcome | Hepatitis C, Chronic - drug therapy | Liver Cirrhosis - virology | RNA, Viral | Uridine Monophosphate - analogs & derivatives | Hepacivirus - classification | Virus diseases | Medical colleges | Care and treatment | Gastrointestinal diseases | Transplantation of organs, tissues, etc | Product development | Research institutes | Hepatitis C virus | Health aspects | Ribavirin | Analysis | Hypothesis testing | Genotype & phenotype | Hepatitis | Liver diseases | Transplants & implants | Liver | Mortality | Infections
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
14. Full Text Nucleotide Polymerase Inhibitor Sofosbuvir plus Ribavirin for Hepatitis C
by Gane, Edward J and Stedman, Catherine A and Hyland, Robert H and Ding, Xiao and Svarovskaia, Evguenia and Symonds, William T and Hindes, Robert G and Berrey, M. Michelle
The New England Journal of Medicine, ISSN 0028-4793, 01/2013, Volume 368, Issue 1, pp. 34 - 44
In this small, preliminary study of sofosbuvir, a nucleotide inhibitor of HCV polymerase, treatment with sofosbuvir and ribavirin, without peginterferon, was... 
GENOTYPE 1 | PSI-7977 | MEDICINE, GENERAL & INTERNAL | VIRUS-INFECTION | THERAPY | REPLICATION | RESISTANCE | REPLICON RNA-SYNTHESIS | COMBINATION | TREATMENT-NAIVE PATIENTS | PROTEASE | Recombinant Proteins - therapeutic use | Humans | Middle Aged | Hepacivirus - genetics | Polyethylene Glycols - adverse effects | Male | Recombinant Proteins - adverse effects | Polyethylene Glycols - therapeutic use | Viral Load | Adult | Female | RNA, Viral - metabolism | Uridine Monophosphate - adverse effects | Drug Therapy, Combination | Uridine Monophosphate - therapeutic use | Hepacivirus - isolation & purification | Antiviral Agents - therapeutic use | Ribavirin - therapeutic use | Interferon-alpha - therapeutic use | Hemoglobins - metabolism | Genotype | Hepatitis C, Chronic - drug therapy | Hepatitis C, Chronic - blood | Ribavirin - adverse effects | Antiviral Agents - adverse effects | Uridine Monophosphate - analogs & derivatives | Aged | Interferon-alpha - adverse effects | Viral Nonstructural Proteins - antagonists & inhibitors | Sofosbuvir | Drugs | Dose-response relationship (Biochemistry) | Antiviral agents | Usage | Patient outcomes | Dosage and administration | Product/Service Evaluations | Drug therapy, Combination | Hepatitis C | Drug therapy | Ribavirin | Hepatitis | Interferon | Infections | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
15. Full Text Nadolol reduces insulin sensitivity in liver cirrhosis: a randomized double-blind crossover trial
: Nadolol and insulin sensitivity
by Lee, Wai Gin and Murphy, Rinki and McCall, John L and Gane, Edward J and Soop, Mattias and Tura, Andrea and Plank, Lindsay D
Diabetes/Metabolism Research and Reviews, ISSN 1520-7552, 03/2017, Volume 33, Issue 3, p. e2859
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
16. Full Text Sofosbuvir for Previously Untreated Chronic Hepatitis C Infection
by Lawitz, Eric and Mangia, Alessandra and Wyles, David and Rodriguez-Torres, Maribel and Hassanein, Tarek and Gordon, Stuart C and Schultz, Michael and Davis, Mitchell N and Kayali, Zeid and Reddy, K. Rajender and Jacobson, Ira M and Kowdley, Kris V and Nyberg, Lisa and Subramanian, G. Mani and Hyland, Robert H and Arterburn, Sarah and Jiang, Deyuan and McNally, John and Brainard, Diana and Symonds, William T and McHutchison, John G and Sheikh, Aasim M and Younossi, Zobair and Gane, Edward J
The New England Journal of Medicine, ISSN 0028-4793, 05/2013, Volume 368, Issue 20, pp. 1878 - 1887
In two studies of sofosbuvir for previously untreated HCV infection, patients with genotype 1, 4, 5, or 6 had a 90% rate of sustained virologic response in a... 
ALPHA-2A | MEDICINE, GENERAL & INTERNAL | PLUS RIBAVIRIN | VIRUS-INFECTION | POLYMERASE | UPDATE | PREVALENCE | Recombinant Proteins - therapeutic use | Humans | Middle Aged | Hepacivirus - genetics | Hepatitis C, Chronic - virology | Polyethylene Glycols - adverse effects | Male | RNA, Viral - blood | Recombinant Proteins - adverse effects | Polyethylene Glycols - therapeutic use | Young Adult | Adult | Female | Uridine Monophosphate - adverse effects | Drug Therapy, Combination | Uridine Monophosphate - therapeutic use | Antiviral Agents - therapeutic use | Ribavirin - therapeutic use | Interferon-alpha - therapeutic use | Genotype | Logistic Models | Hepatitis C, Chronic - drug therapy | Liver Cirrhosis - virology | Ribavirin - adverse effects | Antiviral Agents - adverse effects | Uridine Monophosphate - analogs & derivatives | Aged | Interferon-alpha - adverse effects | Sofosbuvir | Antiviral agents | Complications and side effects | Causes of | Dosage and administration | Research | Hepatitis C virus | Blood diseases | Headache | Clinical trials | Chronic infection | Fatigue | Nausea | Ribavirin | Studies | Genotype & phenotype | Hepatitis | Hepatitis C | Drug therapy | Drug dosages | Genotypes | Neutropenia
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights